REGISTER BY 29TH JUNE AND RECEIVE A £300 DISCOUNT SMi present their 4th annual conference on… COPD Novel Therapeutics and Management Strategies Monday 22nd and Tuesday 23rd October 2012, Copthorne Tara Hotel, London KEY SPEAKERS INCLUDE: Sebastian Johnston Matthew Catley Professor of Respiratory Medicine Team Leader, R&I Imperial College School of Medicine AstraZeneca (N.H.L.I) Nestor Molfino Frank Thielmann Vice –President, Clinical Operational Lead, Inhalation New Development Solids Medimmune Novartis Edwin Chilvers Dirk Bredbroeker Professor of Respiratory Medicine Head of Clinical Science Respiratory University of Cambridge Takeda Ewan Walters Wisia Wedzicha Medical Director Professor of Respiratory Medicine Teva UK University College London Liz Hardaker Louise Donnelly Senior Investigator Reader in Respiratory Cell Biology Novartis Imperial College London WHY ATTEND THIS EVENT: • Consider developments in the modelling and management of exacerbations of COPD • Evaluate unique complexities of COPD pathophysiology - compare and contrast COPD with Asthma to improve your understanding of what makes COPD unique and needing of particular attention • Develop combination and oxygen therapies within COPD - learn about triple therapies and novel therapies within the treatment of COPD • Hear from leading industry professionals on the current clinical trials process and rapid proof of concept studies • Analyse all phases of the discovery process, from pre-clinical modelling, phase 2 studies all the way through to modelling clincal outcomes. • Network with and learn from key industry professionals and research leading academics • Discuss the latest in health economics for COPD drugs PLUS TWO INTERACTIVE HALF-DAY POST-CONFERENCE WORKSHOPS Wednesday 24th October 2012, Copthorne Tara Hotel, London A: Developing Inhalation Devices B: Biomarkers in Respiratory Diseases Workshop Leader: Sabine Haeussermann, Senior Director, Scientific Workshop Leaders: Magnus Nord, Senior Translational Scientist, Business Development, Inamed GmbH AstraZeneca & Karin von Wachenfeldt, Co-Founder, Truly Translational AB 8.30am – 12.30pm 1.00pm-5.30pm Sponsored bywww.copd-conference.co.ukRegister online and receive full information on all of SMi’s conferencesAlternatively fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711
COPD: Novel Therapeutics & Management Strategies 2012Day One | Monday 22nd October 2012 www.copd-con8.30 Registration and Coffee 13.00 Networking LunchMANAGEMENT STRATEGIES9.00 Chairman’s Opening Remarks MANAGEMENT STRATEGIES Sebastian Johnston, Professor of Respiratory Medicine, Imperial College School of Medicine (N.H.L.I.) 14.20 Effective management of COPD • What are the burdens to society, the patient and to the economy? CURRENT DEVELOPMENTS IN THE FIELD • What is the root of these problems?9.10 Current overview of the COPD field • Computer guided diagnosis and treatment algorithms • Mechanisms of exacerbations of COPD • Lessons from Asthma that we can use in COPD • Novel treatment strategies Ewan Walters, Medical Director, Teva UK • What does the future hold in terms of drug development Sebastian Johnston, Professor of Respiratory Medicine, Imperial 15.00 COPD and co-morbidity College School of Medicine (N.H.L.I.) • What are the associations between COPD and co-morbidity? • Why is this important?9.50 Anti-inflammatory drugs in COPD • What is the relevance in pharmaceutical studies? • Rationale and unmet needs John Hurst, Senior Clinical Lecturer, University College London • Potential benefits: from prevention to restructuring • Challenges in drug development: how to translate into clinical benefit? 15.40 Afternoon Tea Daniel Bock, Chief Scientific Officer, Revotar 16.10 Clinical trial design considerations10.30 Morning Coffee • Understanding current clinical trial guidelines for COPD • Are exacerbations the most relevant outcome parameters in COPD11.00 Immunology of COPD clinical trials • Innate immune responses • Long term observation • Adaptive immune responses • Short term studies • Comparing and contrasting different responses Christine Tiesler, Associate Director, Late Stage Research, PPD • Loss of regulation Matthew Catley, Team Leader, R&I, AstraZeneca 16.50 From molecule to medicine; obstacles on the way from discovery to11.40 Combination therapies in COPD market • Unmet needs in the management of COPD patients • Oral or inhaled? Developability assessment of new compounds in the • Scientific rationale for combination therapies treatment of COPD • Delivering inhaled combination therapy • Physical properties and stability – a good drug doesn´t always make a • Discussion into future developments in the field good product Geoff Down, Chief Medical Officer, Prosonix • DPI, MDI or nebuliser? Selection criteria from the products point of view • Manufacturing challenges for inhaled drug products12.20 Measuring neutrophil kinetics in COPD • The future of development and manufacturing of inhaled products • Use of radiolabelled neutrophils to quantify lung inflammation • Kinetics and fate of circulating neutrophils in man Frank Thielmann, Operational Lead Inhalation New Solids, Novartis • Early studies of intravascular kinetics and fate of human eosinophils • Opportunity to use radiolabelled inflammatory cells to perform 17.30 Chairman’s Closing Remarks proof of principle therapeutic trials Edwin Chilvers, Professor of Respiratory Medicine, University of Cambridge 17.40 Close of Day One Register online at www.copd-conference.co.uk • Alternatively fax Sponsored by Biomedical Systems is a global leader in centralized diagnostic services offering a full suite of services for Cardiac Safety and Efficacy, Pulmonary Function Testing including Spirometry, Peak Flow, Nitric Oxide,... and digital Medical Imaging for clinical trials, from classical imaging modalities as well as centralized EEG, Gait and Digital Pathology. www.biomedsys.com Vitalograph has manufactured respiratory diagnostic equipment for the healthcare industry since 1963 and the name Vitalograph is synonymous with spirometry around the world. The name Vitalograph is also synonymous with quality, as many of our spirometers in everyday use are more than 30 years old! As a consequence, our equipment is favoured by opinion leaders and clinical researchers who need reliable and accurate measurements. We provide a full range of services within respiratory clinical trials and this includes project management, centralized data management, over-reading and a global 24/7 support service. We also have a dedicated integrated solution via our Spirotrac® Centralized Spirometry System that includes site based FeNO measurements, 6MWT, pulse oximetry, challenge testing, 12-lead ECG and our exciting new In2itive™ e-Diary that complies with FDA‘s PRO guidance with validated questionnaires. All data is accessible via our VIEWER™ web portal. Also ask about our unique new AIM inhaler trainer for pMDIs and DPIs. www.vitalograph.co.uk Supported by
nference.co.uk Day Two | Tuesday 23rd October 2012 8.30 Re-registration and Coffee DRUG DEVELOPMENT AND NOVEL TARGETS 9.00 Chairmans Opening Remarks 14.20 COPD as systemic disease – Implications for drug development Wisia Wedzicha, Professor of Respiratory Medicine, University College • Role of co-morbidities in COPD London • Cardiovascular Outcomes and COPD EXACERBATION PREVENTION • New trial designs and endpoints needed for COPD to address a new paradigm? 9.10 Managing COPD exacerbations Dirk Bredenbröker, Senior Director, Head of Medical Strategy, R&D, • Guidelines for COPD exacerbation prevention Takeda • Novel bronchodilator approaches for exacerbation prevention • Combination therapy with ICS and exacerbation prevention • Phosphodiesterase inhibitors eg roflumilast and other anti- 15.00 New strategies for bacterial infections in COPD inflammatory therapy • Effects of respiratory tract infections • Can managing the acute exacerbation affect exacerbation frequency? • New ways to prevent infections in COPD Wisia Wedzicha, Professor of Respiratory Medicine, University College • Novel strategies to treat bacterical infections London Nestor Molfino, Vice President, Clinical Development, Medimmune 9.50 Targeting exacerbations of COPD • Brief overview of exacerbations 15.40 Afternoon Tea • Developing pre-clinical models of acute COPD exacerbations • Limitations of pre-clinical models 16.10 CXCR2 antagonists as treatment for COPD • Looking to the future of treating exacerbations • Neutrophilic inflammation in COPD Liz Hardaker, Senior Investigator, Novartis • Why target CXCR2? 10.30 Morning Coffee • Novel CXCR2 antagonists • Current trials of CXCR2 11.00 COPD exacerbations, preventing and changing their natural history Louise Donnelly, Reader in Respiratory Cell Biolog, Imperial College using the tools that we have London (N.H.L.I) • Use of ‘innovative endpoints’ • Case Study: Current situation in the NHS • Learning from the past to develop the future 16.50 RC-Kinase; a novel target implicated in COPD Nabil Jarad, Consultant Respiratory Physician, Bristol Royal Infirmary • Effects of small molecule inhibitors in mouse models of smoke-induced inflammation and fibrosis 11.40 Novel strategies in exacerbation management • Identification and characterization of a novel COPD-relevant kinase • Exacerbation definitions • Immune mechanisms • Impact of exacerbations • Exacerbation prevention • Generation of small molecule inhibitors and characterization in • Treatment of exacerbations smoking, fibrosis and oncology models relevant to COPD and its William MacNee, Professor of Respiratory and Environmental Medicine, co-morbidities University of Edinburgh Kevin Bacon, CSO, Axikin Pharmaceuticals 12.20 Session Reserved for Vitalograph Senior Representative, Vitalograph 17.30 Chairman’s Closing Remarks 13.00 Networking Lunch 17.40 Close of Day Twox your registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711 SMis Pharmaceutical Forward Planner 2012 SPONSORSHIP AND EXHIBITION OPPORTUNITIES JULY 24-25 Biosimilars and 29-30 European SMi offer sponsorship, exhibition, advertising and branding 2-3 KOL Management and MSL Biobetters Pharmaceutical Pricing packages, uniquely tailored to complement your company’s Best Practice in Europe 26-27 KOL Management & Reimbursement marketing strategy. Prime networking opportunities exist to (Switzerland) entertain, enhance and expand your client base within the 9-10 ADMET OCTOBER NOVEMBER context of an independent discussion specific to your 9-10 Social Media in the 3-4 Partnerships with CROs 5-6 Cell Based Assays industry. Should you wish to join the increasing number of Pharmaceutical Industry 8-9 Pharmaceutical Orphan 5-6 Clinical Trials in CNS companies benefiting from sponsoring our conferences 11-12 BioBanking Drugs 28-29 Diabetes please call: Alia Malick on +44 (0) 20 7827 6168 or email: 22-23 COPD: Novel email@example.com Therapeuticsand DECEMBER SEPTEMBER Management Strategies 3-4 Cold Chain Distribution Want to know how you can get involved? Interested in 17-18 Next Generation 24-25 Point of Care Diagnostics promoting your pharmaceutical services to this market? Sequencing - Market Opportunities All conferences take place in 19-20 Cancer Vaccines and Technology Trends central London, UK – unless Contact Kellee Halliburton, SMi Marketing on indicated otherwise in brackets +44 20 7827 6194 or email firstname.lastname@example.org
HALF-DAY POST-CONFERENCE AM WORKSHOP 8.30am – 12.30pm Wednesday 24th October 2012 Copthorne Tara Hotel, London A: Developing Inhalation Devices Workshop Leader: Sabine Häußermann, Director Business Development, Inamed In association withOverview of workshopInhalation techniques and the inhalation device in use play animportant role in the success of inhaled drugs. Often drugs arenot effective and therefore not successful on the market – thereason for which is that the dose which reaches the target regionin the lungs is too small. This workshop will deal with inhalationdevices and inhalation techniques, as well as with the design ofclinical trials for successfully inhaled drugs.Why you should attend:• Learn how best to develop and apply inhalation techniques• Discover the challenges within device development• Utilize the experience of an expert in the field• Develop strategies to improve success of clinical trials• Evaluate current European guidelines and what they mean for the industry• Network with key industry professionalsProgramme8.30 Registration & Coffee9.00 Welcome & Introductions9.10 Overview of developing inhalation devices for COPD • Developing techniques in inhalation device design • Strategies to make the development process more efficient • Overcoming common challenges in device development9.45 Case Study -Inhalation devices for generic products in the EU and the US • Problems encountered • How were these obstacles overcome • What the future holds10.45 Tea Break11.00 Application / Inhalation devices in clinical trials and in practice • Clinical Trial design analysis • Information on the specifics of clinical trials for inhaled drugs12.10 Discussion Session12.30 Close of workshopAbout the workshop host Dr Sabine Häußermann, Director Business Development, Inamed Dr. Häußermann has worked for Inamed in her current role, since March 2010 and is responsible for scientific advice and regulatory services. Dr. Häußermann is an engineer by training andstarted out her career in basic research on the inhalation ofaerosols in the Institute of Inhalation Biology at the HelmholzCenter in Neuherberg, Munich in Prof. Heyders group.After obtaining her PhD, she previously worked for Inamed from2000 to 2006, applying her research to the pharmaceutical fieldof respiratory aerosol medicine, initially as project manager.From 2002 she headed the clinical research group at Inamed inGauting, before moving to France. From 2006 to 2010 sheheaded the inhalation device development section in the medicalgases research group at Air Liquide.Dr. Häußermann is an active member of the ISAM society, haschaired the ISAM Awards Committee and is now a member ofthe ISAM board.About INAMEDComplementing our solid experience in conducting clinical trialsand our staffed, in-house Phase I unit, Inamed performs in-vitrostudies in our own labs and performs radio-labeling studies.With over two decades of clinical research experience, ourclients benefit from our state-of-the-art infrastructure, long-term experience and network of competent partners. Inamedenable its sponsors to reach better go" or "no-go” decisions tolaunch and market their products successfully.
HALF-DAY POST-CONFERENCE PM WORKSHOP 1.00pm – 5.30pm Wednesday 24th October 2012 Copthorne Tara Hotel, London Biomarkers in Respiratory Diseases -What can they deliver, and for who do we generate the results ? Workshop Leaders: Magnus Nord, Senior Translational Scientist, AstraZeneca & Karin von Wachenfeldt, Co-Founder, Truly Translational AB In association with AstraZeneca & Truly TranslationalOverview of workshopThis unique workshop will allow attendees to discuss the latestdevelopments within translational biomarkers and how they canbe used in COPD drug development. This case-study led sessionwill present attendees with success stories to learn from andadapt into their own drug development programs. Withbiomarkers playing a larger and more important role in COPDdrug development, this workshop is not to be missed.Why you should attend:• Learn how best to develop pre-clinical biomarker discovery• Consider the latest obstacles in biomarker discovery and how to overcome them• Develop imaging technologies to improve biomarker development in COPD• Network with key industry professionalsProgramme1.00 Registration & Coffee1.30 Welcome & Introductions1.45 Overview of Biomarkers for Efficacy2.15 Overview of Biomarkers for Safety2.45 Afternoon Tea3.00 Challenges in Biomarker development in the respiratory field - COPD. • Circulating biomarkers • Imaging as biomarker? • Validation challenges, and reasons to collaborate.4.00 Challenges in Biomarker development in the respiratory field - Drug-induced Interstitial Lung Disease • Strategies for discovery • Imaging vs circulating biomarkers • Challenges in clinical qualification5.00 Discussion Session5.30 Close of WorkshopAbout the workshop hosts:Dr Magnus Nord, MD, PhD, Assoc Prof, holds a position in SafetyScience, a Global Enabling Science Function in AstraZenecaPatient Safety. It is a focused group of scientists, physicians,statisticians and informaticians working to shape clinical safetyand support decision-making in drug projects. Magnus is alsochairman and clinical lead of the AstraZeneca Pulmonary SafetyKnowledge Group and has to date published 40+ scientific articles.Dr Karin von Wachenfeldt, CEO and Co-founder of TrulyTranslational Sweden, an Immunologist by training, and with astrong scientific interest in understanding why people developdisease, and how diseases can be treated or prevented. For 12years she held different leading biology positions at AstraZeneca,always with a focus on increasing the understanding of underlyingdisease mechanisms, and how to translate these to drug targets.At AZ she pioneered the use of biomarkers in early clinical trials,and how these can be used for decision making. Since 2011 sheheads up Truly Translational Sweden AB a company focusingentirely on translational sciences, offering senior consultancyservices.About AstraZeneca:AstraZeneca is a global, innovation-driven, integratedbiopharmaceutical company. They discover, develop manufactureand market prescription medicines for six important areas ofhealthcare, which include some of the world’s most seriousillnesses: cancer, cardiovascular, gastrointestinal infection,neuroscience, and respiratory and inflammation.About Truly Translational:Truly Translational Sweden AB provides life science and drugdevelopment consultancy with an emphasis on biology andtranslational science. Our mission is to translate preclinical projectideas into efficient development plans delivering successfulclinical trials. Truly Translational is founded on solid scientificexpertise and more than 50 years experience with drug researchand development in both large pharma and biotech. We focus onbringing biologicals and small molecule projects from preclinicalin vitro studies and animal models via common biomarkerstrategies, into concept testing in patients.
COPD: NOVEL THERAPEUTICS AND MANAGEMENT STRATEGIES Conference: Monday 22nd and Tuesday 23rd October 2012, Copthorne Tara Hotel, London, UK Workshops: Wednesday 24th October 2012, London, UK 4 WAYS TO REGISTER www.copd-conference.co.ukFAX your booking form to +44 (0) 870 9090 712 POST your booking form to: Events Team, SMi Group Ltd, 2nd Floor South,PHONE on +44 (0) 870 9090 711 Harling House, 47-51 Great Suffolk Street, London, SE1 0BS, UK EARLY BIRD □ Book by 29th June 2012 to receive a £300 off the conference price DISCOUNT CONFERENCE PRICES I would like to attend: (Please tick as appropriate) Fee Total □ Conference & 2 Workshops £2697.00 + VAT £3236.40 □ Conference & 1 Workshop £2098.00 + VAT £2517.60 □ Conference only £1499.00 + VAT £1798.80 □ 1 Workshop only £599.00 + VAT £718.80Unique Reference Number □ 2 Workshops £1198.00 + VAT £1437.60 Workshop A □ Workshop B □Our Reference LVP-048 PROMOTIONAL LITERATURE DISTRIBUTIONDELEGATE DETAILS □ Distribution of your company’s promotional literature to all conference attendees £999.00 + VAT £1198.80Please complete fully and clearly in capital letters. Please photocopy for additional delegates.Title: Forename: GROUP DISCOUNTS AVAILABLESurname: The conference fee includes refreshments, lunch, conference papers and access to the Document Portal containing all of the presentations.Job Title:Department/Division:Company/Organisation: VENUE Copthorne Tara Hotel, Scarsdale Place, Kensington, London W8 5SREmail: □ Please contact me to book my hotelCompany VAT Number: Alternatively call us on +44 (0) 870 9090 711,Address: email: email@example.com or fax +44 (0) 870 9090 712Town/City: DOCUMENTATIONPost/Zip Code: Country: I cannot attend but would like to purchase access to the following DocumentDirect Tel: Direct Fax: Portal/paper copy documentation Price Total □ Access to the conference documentationMobile: on the Document Portal £499.00 + VAT £598.80Switchboard: □ The Conference Presentations – paper copy £499.00 - £499.00 (or only £300 if ordered with the Document Portal)Signature: Date:I agree to be bound by SMis Terms and Conditions of Booking.ACCOUNTS DEPT PAYMENTTitle: Forename: Payment must be made to SMi Group Ltd, and received before the event, by one of theSurname: following methods quoting reference P-048 and the delegate’s name. Bookings made within 7 days of the event require payment on booking, methods of payment are below. PleaseEmail: indicate method of payment:Address (if different from above): □ UK BACS Sort Code 300009, Account 00936418 □ Wire Transfer Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU Swift (BIC): LOYDGB21013, Account 00936418Town/City: IBAN GB48 LOYD 3000 0900 9364 18 □ Cheque We can only accept Sterling cheques drawn on a UK bank.Post/Zip Code: Country: □ Credit Card □ Visa □ MasterCard □ American ExpressDirect Tel: Direct Fax: All credit card payments will be subject to standard credit card charges. Card No: □□□□ □□□□ □□□□ □□□□Terms and Conditions of Booking Valid From □□/□□ Expiry Date □□/□□ CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX cardPayment: If payment is not made at the time of booking, then an invoice will be issued and must bepaid immediately and prior to the start of the event. If payment has not been received then credit carddetails will be requested and payment taken before entry to the event. Bookings within 7 days ofevent require payment on booking. Access to the Document Portal will not be given until paymenthas been received. Cardholder’s Name:Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, anotherdelegate to take your place at any time prior to the start of the event. Two or more delegates maynot ‘share’ a place at an event. Please make separate bookings for each delegate. Signature: Date:Cancellation: If you wish to cancel your attendance at an event and you are unable to send a I agree to be bound by SMis Terms and Conditions of Booking.substitute, then we will refund/credit 50% of the due fee less a £50 administration charge,providing that cancellation is made in writing and received at least 28 days prior to the start of the Card Billing Address (If different from above):event. Regretfully cancellation after this time cannot be accepted. We will however provide theconferences documentation via the Document Portal to any delegate who has paid but is unable toattend for any reason. Due to the interactive nature of the Briefings we are not normally able toprovide documentation in these circumstances. We cannot accept cancellations of orders placedfor Documentation or the Document Portal as these are reproduced specifically to order. If we haveto cancel the event for any reason, then we will make a full refund immediately, but disclaim anyfurther liability.Alterations: It may become necessary for us to make alterations to the content, speakers, timing,venue or date of the event compared to the advertised programme.Data Protection: The SMi Group gathers personal data in accordance with the UK Data ProtectionAct 1998 and we may use this to contact you by telephone, fax, post or email to tell you about other VATproducts and services. Unless you tick here □ we may also share your data with third parties VAT at 20% is charged on the attendance fees for all delegates. VAT is also charged on Documentoffering complementary products or services. If you have any queries or want to update any of thedata that we hold then please contact our Database Manager firstname.lastname@example.org Portal and Literature Distribution for all UK customers and for those EU customers not supplyingor visit our website www.smi-online.co.uk/updates quoting the URN as detailed above youraddress on the attached letter. a registration number for their own country here: ______________________________________ If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email them at email@example.com